10x Genomics, Inc. reported products and services revenue of $150.2 million for the three months ended September 30, 2026, up 1%, while gross margin rose to 75%. It agreed to acquire Proteintech Genomics, Inc. for $6.1 million.
TXG · 10x Genomics, Inc. · Documents
You came from your AI assistant. Add Equibles to it and ask about this data directly, free.
The company's filings, earnings calls and investor events, most recent first. Search and read these filings from Claude or ChatGPT with the SEC filings MCP server →
10x Genomics reported third-quarter revenue of $150.7 million, up 1%, raised its 2026 revenue outlook to $625 million to $635 million and expects approximately 50 ATERRA instruments by year-end, up from approximately 40.
10x Genomics, Inc. reported third-quarter 2026 revenue of $150.7 million, up 1% year over year, and net loss of $19.4 million; it raised full-year revenue guidance to $625 million to $635 million.
10x Genomics appointed Ansuman Satpathy and Joseph Gilliam to its Board of Directors as Class III directors effective October 28, 2026. Gilliam was also named Audit Committee Chair on October 30, 2026, with a $25,000 annual retainer.